{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:53:10Z","timestamp":1777870390429,"version":"3.51.4"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40620-019-00663-6","type":"journal-article","created":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T21:19:55Z","timestamp":1571951995000},"page":"569-581","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Identifying Fabry patients in dialysis population: prevalence of GLA mutations by renal clinic screening, 1995\u20132019"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6559-196X","authenticated-orcid":false,"given":"Ivana","family":"Capuano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Garofalo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Buonanno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Pinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teodolinda","family":"Di Risi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Feriozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Riccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,10,24]]},"reference":[{"issue":"2","key":"663_CR1","first-page":"1","volume":"35","author":"G Alfano","year":"2018","unstructured":"Alfano G, Ganda N, Cerami C et al (2018) Screening test of Fabry disease in patients with renal replacement therapy in the city of Modena. G Ital Nefrol 35(2):1\u201313","journal-title":"G Ital Nefrol"},{"issue":"4","key":"663_CR2","first-page":"83","volume":"34","author":"P Bolasco","year":"2017","unstructured":"Bolasco P, Sitzia I, Murtas S (2017) Fabry Disease in Southern Sardinia: epidemiological results from screening in an extensive area. G Ital Nefrol 34(4):83\u2013102","journal-title":"G Ital Nefrol"},{"key":"663_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9734\/BJMMR\/2017\/32156","volume":"21","author":"M Coutinho","year":"2017","unstructured":"Coutinho M, Neto O, Ara\u00fajo J et al (2017) Screening for Fabry disease among dialysis patients in Brazil: findings from the first 18\u00a0months of a Nationwide study. Br J Med Med Res 21:1\u201316","journal-title":"Br J Med Med Res"},{"issue":"Suppl","key":"663_CR4","first-page":"1","volume":"43","author":"R Maslauskien\u0117","year":"2007","unstructured":"Maslauskien\u0117 R, Bumblyt\u0117 IA, \u0160ileikien\u0117 E et al (2007) The prevalence of Fabry\u2019s disease among male patients on hemodialysis in Lithuania (a screening study). Medicina (Kaunas) 43(Suppl):1","journal-title":"Medicina (Kaunas)"},{"key":"663_CR5","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/ndt\/gfp105","volume":"24","author":"B Oqvist","year":"2009","unstructured":"Oqvist B, Brenner BM, Oliveira J et al (2009) Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations. Nephrol Dial Transplant 24:1736\u20131743","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"663_CR6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5414\/CN108672","volume":"85","author":"EI Sayilar","year":"2016","unstructured":"Sayilar EI, Ayar Y, Yavuz M (2016) Prevalence of Fabry disease among Turkish dialysis patients: data from hemodialysis centers in Bursa province. Clin Nephrol 85(3):165\u2013172","journal-title":"Clin Nephrol"},{"issue":"4","key":"663_CR7","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3904\/kjim.2010.25.4.415","volume":"25","author":"JY Kim","year":"2010","unstructured":"Kim JY, Hyun YY, Lee JE et al (2010) Serum globotriaosylceramide assay as a screening test for fabry disease in patients with ESRD on maintenance dialysis in Korea. Korean J Intern Med 25(4):415\u2013421","journal-title":"Korean J Intern Med"},{"issue":"1","key":"663_CR8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2215\/CJN.02490607","volume":"3","author":"J Andrade","year":"2008","unstructured":"Andrade J, Waters PJ, Singh RS et al (2008) Screening for Fabry disease in patients with chronic kidney disease: limitations of plasma alpha-galactosidase assay as a screening test. Clin J Am Soc Nephrol 3(1):139\u2013145 (Epub 2007 Nov 14)","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"663_CR9","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/01.ASN.0000124671.61963.1E","volume":"15","author":"P Kotanko","year":"2004","unstructured":"Kotanko P, Kramar R, Devrnja D et al (2004) Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 15(5):1323\u20131329 (Erratum in: J Am Soc Nephrol. 2004 Sep;15(9):A4. J Am Soc Nephrol. 2004 Aug;15(8):1a)","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"663_CR10","first-page":"129","volume":"1","author":"VI Rasaiah","year":"2008","unstructured":"Rasaiah VI, Underwood JP, Oreopoulos DG et al (2008) Implementation of high-throughput screening for Fabry disease in Toronto dialysis patients. NDT Plus. 1(2):129\u2013130","journal-title":"NDT Plus."},{"key":"663_CR11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1080\/08860220802353777","volume":"30","author":"DB Porsch","year":"2008","unstructured":"Porsch DB, Fernandes Nunes AC, Milani V et al (2008) Fabry disease in hemodialysis patients in Southern Brazil: prevalence study and clinical report. Ren Fail 30:825\u2013830","journal-title":"Ren Fail"},{"issue":"3","key":"663_CR12","first-page":"144","volume":"61","author":"SN Kabalan","year":"2013","unstructured":"Kabalan SN, Abbas S, Tawil L (2013) A search for Fabry disease among male end-stage renal disease patients in Lebanon and a review of the literature. Med Liban 61(3):144\u2013147","journal-title":"Med Liban"},{"issue":"1","key":"663_CR13","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/ndt\/gfm532","volume":"23","author":"W Terryn","year":"2008","unstructured":"Terryn W, Poppe B, Wuyts B et al (2008) Two-tier approach for the detection of alpha-galactosidase A deficiency in a predominantly female haemodialysis population. Nephrol Dial Transplant 23(1):294\u2013300","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"663_CR14","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","volume":"64","author":"S Nakao","year":"2003","unstructured":"Nakao S, Kodama C, Takenaka T et al (2003) Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype. Kidney Int 64(3):801\u2013807","journal-title":"Kidney Int"},{"key":"663_CR15","unstructured":"Green JPHS (2011) Cochrane handbook for systematic reviews of interventions. \nhttp:\/\/www.cochrane.org\/training\/cochrane-handbook\n\n. Accessed 9 Apr 2016"},{"issue":"15","key":"663_CR16","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008\u20132012","journal-title":"JAMA"},{"issue":"7414","key":"663_CR17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560","journal-title":"BMJ"},{"issue":"6","key":"663_CR18","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1159\/000485929","volume":"42","author":"LSS Sodr\u00e9","year":"2017","unstructured":"Sodr\u00e9 LSS, Huaira RMNH, Bastos MG et al (2017) Screening for Fabry disease in kidney disease: a cross-sectional study in males and females. Kidney Blood Press Res 42(6):1258\u20131265","journal-title":"Kidney Blood Press Res"},{"issue":"4","key":"663_CR19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.5414\/CNP64281","volume":"64","author":"M Tanaka","year":"2005","unstructured":"Tanaka M, Ohashi T, Kobayashi M et al (2005) Identification of Fabry\u2019s disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients. Clin Nephrol 64(4):281\u2013287","journal-title":"Clin Nephrol"},{"issue":"2","key":"663_CR20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1399-0004.2009.01166.x","volume":"76","author":"YL Lv","year":"2009","unstructured":"Lv YL, Wang WM, Pan XX et al (2009) A successful screening for Fabry disease in a Chinese dialysis patient population. Clin Genet 76(2):219\u2013221","journal-title":"Clin Genet"},{"issue":"4","key":"663_CR21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2215\/CJN.08780812","volume":"8","author":"H Maruyama","year":"2013","unstructured":"Maruyama H, Takata T, Tsubata Y et al (2013) Screening of male dialysis patients for Fabry disease by plasma globotriaosylsphingosine. Clin J Am Soc Nephrol 8(4):629\u2013636","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"663_CR22","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1093\/ndt\/gfg194","volume":"18","author":"GE Linthorst","year":"2003","unstructured":"Linthorst GE, Hollak CE, Korevaar JC et al (2003) Alpha-galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease. Nephrol Dial Transplant 18(8):1581\u20131584","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"663_CR23","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3109\/0886022X.2012.669300","volume":"34","author":"T Nishino","year":"2012","unstructured":"Nishino T, Obata Y, Furusu A et al (2012) Identification of a novel mutation and prevalence study for fabry disease in Japanese dialysis patients. Ren Fail 34(5):566\u2013570","journal-title":"Ren Fail"},{"key":"663_CR24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s101570050061","volume":"4","author":"K Utsumi","year":"2000","unstructured":"Utsumi K, Kase R, Takata T et al (2000) Fabry disease in patients receiving maintenance dialysis. Clin Exp Nephrol 4:49\u201351","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"663_CR25","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1159\/000492593","volume":"43","author":"C Zizzo","year":"2018","unstructured":"Zizzo C, Testa A, Colomba P et al (2018) Systematic DNA study for Fabry disease in the end stage renal disease patients from a southern Italy area. Kidney Blood Press Res 43(4):1344\u20131351","journal-title":"Kidney Blood Press Res"},{"issue":"5","key":"663_CR26","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","volume":"333","author":"S Nakao","year":"1995","unstructured":"Nakao S, Takenaka T, Maeda M et al (1995) An atypical variant of Fabry\u2019s disease in men with left ventricular hypertrophy. N Engl J Med 333(5):288\u2013293","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"663_CR27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0009-8981(01)00478-8","volume":"308","author":"NA Chamoles","year":"2001","unstructured":"Chamoles NA, Blanco M, Gaggioli D (2001) Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta 308(1\u20132):195\u2013196","journal-title":"Clin Chim Acta"},{"key":"663_CR28","doi-asserted-by":"crossref","first-page":"100454","DOI":"10.1016\/j.ymgmr.2019.100454","volume":"19","author":"DP Germain","year":"2019","unstructured":"Germain DP, Elliott PM, Falissard B et al (2019) The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts. Mol Genet Metab Rep 19:100454","journal-title":"Mol Genet Metab Rep"},{"issue":"4","key":"663_CR29","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.tcm.2017.10.001","volume":"28","author":"TR Hsu","year":"2018","unstructured":"Hsu TR, Niu DM (2018) Fabry disease: review and experience during newborn screening. Trends Cardiovasc Med 28(4):274\u2013281","journal-title":"Trends Cardiovasc Med"},{"issue":"4","key":"663_CR30","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jmg.2009.072116","volume":"47","author":"GE Linthorst","year":"2010","unstructured":"Linthorst GE, Bouwman MG, Wijburg FA et al (2010) Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet 47(4):217\u2013222","journal-title":"J Med Genet"},{"issue":"4","key":"663_CR31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/jmedgenet-2017-105080","volume":"55","author":"D Doheny","year":"2018","unstructured":"Doheny D, Srinivasan R, Pagant S et al (2018) Fabry disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995\u20132017. J Med Genet 55(4):261\u2013268","journal-title":"J Med Genet"},{"issue":"6","key":"663_CR32","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1159\/000250968","volume":"30","author":"H Fujii","year":"2009","unstructured":"Fujii H, Kono K, Goto S et al (2009) Prevalence and cardiovascular features of Japanese hemodialysis patients with Fabry disease. Am J Nephrol 30(6):527\u2013535","journal-title":"Am J Nephrol"},{"issue":"9","key":"663_CR33","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/jhg.2012.68","volume":"57","author":"K Doi","year":"2012","unstructured":"Doi K, Noiri E, Ishizu T et al (2012) High-throughput screening identified disease-causing mutants and functional variants of \u03b1-galactosidase A gene in Japanese male hemodialysis patients. J Hum Genet 57(9):575\u2013579","journal-title":"J Hum Genet"},{"issue":"3","key":"663_CR34","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s10157-005-0369-4","volume":"9","author":"M Ichinose","year":"2005","unstructured":"Ichinose M, Nakayama M, Ohashi T et al (2005) Significance of screening for Fabry disease among male dialysis patients. Clin Exp Nephrol 9(3):228\u2013232","journal-title":"Clin Exp Nephrol"},{"key":"663_CR35","first-page":"1","volume":"24","author":"S Moiseev","year":"2019","unstructured":"Moiseev S, Fomin V, Savostyanov K et al (2019) The prevalence and clinical features of Fabry disease in hemodialysis patients: Russian Nationwide Fabry Dialysis Screening Program. Nephron 24:1\u20137","journal-title":"Nephron"},{"issue":"2","key":"663_CR36","doi-asserted-by":"crossref","first-page":"112","DOI":"10.5414\/CN108053","volume":"81","author":"J Herrera","year":"2014","unstructured":"Herrera J, Miranda CS (2014) Prevalence of Fabry\u2019s disease within hemodialysis patients in Spain. Clin Nephrol 81(2):112\u2013120","journal-title":"Clin Nephrol"},{"issue":"6","key":"663_CR37","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1744-9987.2012.01092.x","volume":"16","author":"S Kalkan U\u00e7ar","year":"2012","unstructured":"Kalkan U\u00e7ar S, Sozmen E, Duman S et al (2012) Alpha-galactosidase A activity levels in Turkish male hemodialysis patients. Ther Apher Dial 16(6):560\u2013565","journal-title":"Ther Apher Dial"},{"issue":"4","key":"663_CR38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000448740","volume":"134","author":"CA Silva","year":"2016","unstructured":"Silva CA, Barreto FC, Dos Reis MA et al (2016) Targeted screening of Fabry disease in male hemodialysis patients in Brazil highlights importance of family screening. Nephron 134(4):221\u2013230","journal-title":"Nephron"},{"issue":"2","key":"663_CR39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000479895","volume":"138","author":"VSP Veloso","year":"2018","unstructured":"Veloso VSP, Ataides TL, Canziani MEF et al (2018) A novel missense GLA mutation (p.G35V) detected in hemodialysis screening leads to severe systemic manifestations of Fabry disease in men and women. Nephron 138(2):147\u2013156","journal-title":"Nephron"},{"issue":"6","key":"663_CR40","doi-asserted-by":"crossref","first-page":"506","DOI":"10.5414\/CNP75506","volume":"75","author":"EF Wallin","year":"2011","unstructured":"Wallin EF, Clatworthy MR, Pritchard NR (2011) Fabry disease: results of the first UK hemodialysis screening study. Clin Nephrol 75(6):506\u2013510","journal-title":"Clin Nephrol"},{"issue":"1","key":"663_CR41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1096-7192(02)00012-4","volume":"76","author":"J Shabbeer","year":"2002","unstructured":"Shabbeer J, Yasuda M, Luca E et al (2002) Fabry disease: 45 novel mutations in the alpha-galactosidase A gene causing the classical phenotype. Mol Genet Metab 76(1):23\u201330","journal-title":"Mol Genet Metab"},{"issue":"4","key":"663_CR42","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","volume":"19","author":"ER Benjamin","year":"2017","unstructured":"Benjamin ER, Della Valle MC, Wu X et al (2017) The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med. 19(4):430\u2013438","journal-title":"Genet Med."},{"issue":"1","key":"663_CR43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M et al (2006) High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 79(1):31\u201340","journal-title":"Am J Hum Genet"},{"issue":"3","key":"663_CR44","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1432-2277.2008.00791.x","volume":"22","author":"J Kleinert","year":"2009","unstructured":"Kleinert J, Kotanko P, Spada M et al (2009) Anderson-Fabry disease: a case-finding study among male kidney transplant recipients in Austria. Transpl Int 22(3):287\u2013292","journal-title":"Transpl Int"},{"issue":"4","key":"663_CR45","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/cge.12386","volume":"86","author":"A Pisani","year":"2014","unstructured":"Pisani A, Visciano B, Imbriaco M et al (2014) The kidney in Fabry\u2019s disease. Clin Genet 86(4):301\u2013309","journal-title":"Clin Genet"},{"issue":"2","key":"663_CR46","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/ndt\/gfx009","volume":"33","author":"A Pisani","year":"2018","unstructured":"Pisani A, Petruzzelli Annicchiarico L, Pellegrino A et al (2018) Parapelvic cysts, a distinguishing feature of renal Fabry disease. Nephrol Dial Transplant 33(2):318\u2013323","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"663_CR47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000493469","volume":"141","author":"E Riccio","year":"2019","unstructured":"Riccio E, Sabbatini M, Bruzzese D et al (2019) Glomerular hyperfiltration: an early marker of nephropathy in Fabry disease. Nephron. 141(1):10\u201317","journal-title":"Nephron."},{"issue":"4","key":"663_CR48","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1093\/ehjci\/jey108","volume":"20","author":"R Esposito","year":"2019","unstructured":"Esposito R, Galderisi M, Santoro C et al (2019) Prominent longitudinal strain reduction of left ventricular basal segments in treatment-na\u00efve Anderson-Fabry disease patients. Eur Heart J Cardiovasc Imaging 20(4):438\u2013445","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"7","key":"663_CR49","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00259-015-3036-3","volume":"42","author":"C Nappi","year":"2015","unstructured":"Nappi C, Altiero M, Imbriaco M et al (2015) First experience of simultaneous PET\/MRI for the early detection of cardiac involvement in patients with Anderson\u2013Fabry disease. Eur J Nucl Med Mol Imaging 42(7):1025\u20131031","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"663_CR50","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s13244-018-0664-8","volume":"9","author":"S Cocozza","year":"2018","unstructured":"Cocozza S, Russo C, Pontillo G et al (2018) Neuroimaging in Fabry disease: current knowledge and future directions. Insights Imaging 9(6):1077\u20131088","journal-title":"Insights Imaging"},{"issue":"11","key":"663_CR51","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1097\/TP.0000000000002252","volume":"102","author":"S Ers\u00f6zl\u00fc","year":"2018","unstructured":"Ers\u00f6zl\u00fc S, Desnick RJ, Huynh-Do U, Canaan-K\u00fchl S, Barbey F, Genitsch V, Mueller TF, Cheetham M, Flammer AJ, Schaub S, Nowak A (2018) Long-term outcomes of kidney transplantation in Fabry disease. Transplantation 102(11):1924\u20131933. \nhttps:\/\/doi.org\/10.1097\/TP.0000000000002252","journal-title":"Transplantation"},{"issue":"4","key":"663_CR52","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ et al (2018) Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab 123(4):416\u2013427.\u00a0\nhttps:\/\/doi.org\/10.1016\/j.ymgme.2018.02.014","journal-title":"Mol Genet Metab"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-019-00663-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40620-019-00663-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-019-00663-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:56:23Z","timestamp":1777564583000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/33\/3\/569\/8328428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,24]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["663"],"URL":"https:\/\/doi.org\/10.1007\/s40620-019-00663-6","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,24]]},"assertion":[{"value":"21 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional\u00a0and\/or national research committee and with the 1964 Helsinki declaration\u00a0and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}